The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
An engineered immunotherapy (NKTR-214) with altered selectivity toward the IL2 receptor: Efficacy and tolerability in a murine tumor model.
Deborah H. Charych
Employment or Leadership Position - Nektar
Stock Ownership - Nektar
Murali Addepalli
Employment or Leadership Position - Nektar
Stock Ownership - Nektar
Steve Lee
Employment or Leadership Position - Nektar
Stock Ownership - Nektar
Thomas Chang
Employment or Leadership Position - Nektar
Stock Ownership - Nektar
Xiaofeng Liu
Employment or Leadership Position - Nektar
Stock Ownership - Nektar
Rhoneil Pena
Employment or Leadership Position - Nektar
Stock Ownership - Nektar
Terry Sweeney
Employment or Leadership Position - Nektar
Stock Ownership - Nektar
Ute Hoch
Employment or Leadership Position - Nektar
Stock Ownership - Nektar
Stephen K. Doberstein
Employment or Leadership Position - Nektar
Stock Ownership - Nektar
Seema S. Kantak
Employment or Leadership Position - Nektar
Stock Ownership - Nektar